← Back to Clinical Trials
Recruiting NCT07270185

NCT07270185 Measuring Outcomes With Validated Exercise

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07270185
Status Recruiting
Phase
Sponsor Boston University
Condition Physical Activity
Study Type OBSERVATIONAL
Enrollment 54 participants
Start Date 2025-12-04
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 89 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 54 participants in total. It began in 2025-12-04 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Physical activity and its intensity level is a critical determinant of health. Digital Health Technologies, such as wearable accelerometers (wrist-worn watch-like devices), can provide researchers and clinicians with objective measures of activity intensity, duration, and effect on an individual's physiology which can provide important insight into overall health. The purpose of this observational study is to assess how well wrist-worn devices can measure the intensity of movement and exercise. This study is designed to rigorously validate existing activity classification algorithms using synchronized multi-sensor data and indirect calorimetry during structured, semi-structured, and free-living tasks.

Eligibility Criteria

Inclusion Criteria: * Participant is willing and able to comply with study instructions, study visits, and procedures including wearing a tight-fitting respiratory mask * Able to ambulate independently, including walking/running on a treadmill without assistance. * Demonstrates fluency in English * Montreal Cognitive Assessment (MoCA) score of ≥26 * Score of 100 on the Barthel Index * Participant has reliable access to internet Exclusion Criteria: * Participation in other digital device trials within 1 week or investigational drug trials within 5 half-lives of last dose. * Allergy to polyurethane resin (strap/wristband component), silicone rubber, nickel and/or steel. * Has any planned surgical, dental, or medical procedure that would overlap with study participation. * Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices. * Has any clinically significant medical disorder, condition, disease or clinically significant finding at intake that precludes participant's participation in study activities including any self-reported diagnosis of cardiovascular disease, metabolic disorder, chronic obstructive pulmonary disease, cerebral vascular accident/stroke, stage 2 hypertension, use of any medication which alters heart rate (HR) response (e.g., Beta blockers and calcium blockers), any history of myocardial infarction high-risk unstable angina, uncontrolled cardiac arrhythmias, active endocarditis, symptomatic severe aortic stenosis, decompensated symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, acute noncardiac disorder that my affect exercise performance/be worsened by exercise (e.g., infection, renal failure), acute myocarditis or pericarditis, left main coronary stenosis or its equivalent, moderate stenotic valvular heart disease, electrolyte abnormalities, tachyarrhythmia or bradyarrhythmia's, atrial fibrillation, high-degree Atrioventricular (AV) block, mobility/orthopedic limitations. * Has any skin conditions, open wounds, or other conditions on the wrists that may interfere with wrist-worn wearable sensors. * Has tuberculosis, oral lesions (sores, bleeding gums), any respiratory illnesses, and/or any other known transmissible infectious diseases during subsequent study visits. * Any changes to recorded health status from intake that would deem participant to be ineligible during subsequent study visits. * Has Asthma * Has claustrophobia * Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study. * Has a history of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 12 months of Visit 1 as disclosed by participant during evaluation. * Is a female who is breastfeeding or pregnant, as disclosed by the participant. * Class III Obesity: Body Mass Index (BMI) ≥ 40 kg/m2 * Underweight: BMI \< 18.5 kg/m2 * Resting systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg * Resting heart rate \<40 or ≥ 110 beats/min (for participants ≥60 years) * Current tobacco/nicotine use

Contact & Investigator

Central Contact

Kevin C Thomas, PhD MBA

✉ kipthoma@bu.edu

📞 617-414-2335

Principal Investigator

Kevin C Thomas, PhD MBA

PRINCIPAL INVESTIGATOR

CABUSM, Anatomy and Neurobiology

Frequently Asked Questions

Who can join the NCT07270185 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Physical Activity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07270185 currently recruiting?

Yes, NCT07270185 is actively recruiting participants. Contact the research team at kipthoma@bu.edu for enrollment information.

Where is the NCT07270185 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT07270185 clinical trial?

NCT07270185 is sponsored by Boston University. The principal investigator is Kevin C Thomas, PhD MBA at CABUSM, Anatomy and Neurobiology. The trial plans to enroll 54 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology